FA
XERS icon

Faithward Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Faithward Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-106,730
Closed -$838K – 341
2025
Q4 		$838K Buy
+106,730
New +$840K 0.12% 140

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Faithward Advisors's XERS Position: Q1 2026 in Review

Faithward Advisors sold out of Xeris Biopharma Holdings (XERS) in Q1 2026, closing a stake of 106,730 shares — an estimated $838K sold.

Faithward Advisors first reported a position in XERS in Q4 2025 and held it in 1 quarter. The position peaked at $838K in Q4 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Faithward Advisors reported no remaining Xeris Biopharma Holdings position as of Q1 2026 after selling out during the quarter.
  • Faithward Advisors sold 106,730 Xeris Biopharma Holdings shares in Q1 2026, an estimated $838K.
  • Faithward Advisors first reported a position in Xeris Biopharma Holdings in Q4 2025 and held it in 1 quarter.
  • Faithward Advisors's Xeris Biopharma Holdings position peaked at $838K in Q4 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Faithward Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.